OS Therapies Inc. has formally filed a Biologics License Application (BLA) with the U.S. Food & Drug Administration for its lead product, OST‑HER2, a listeria‑based immunotherapy designed to prevent or delay recurrence in patients with fully resected pulmonary metastatic osteosarcoma. The company has already submitted the non‑clinical and Chemistry, Manufacturing, and Controls (CMC) modules and has requested a rolling review to accelerate the review process.
The filing follows a December 2025 Type C meeting in which the FDA confirmed that single‑arm data could support accelerated approval. OS Therapies is now seeking a Type D meeting in March 2026 to present comparative oncology data from its Phase IIb human trial and a canine trial, leveraging the company’s unique comparative‑oncology platform to strengthen the evidence base.
The company plans to submit the clinical BLA module by the end of March 2026, with the goal of achieving approval before the September 30, 2026 deadline that would qualify it for a Priority Review Voucher. The voucher could be a valuable asset, either for internal use or for sale to other companies seeking expedited review of their own products.
OS Therapies has also updated its regulatory designations: it holds Rare Pediatric Disease Designation, Fast‑Track, and Orphan Drug status for OST‑HER2, and has submitted an update to its Regenerative Medicine Advanced Therapy request. These designations support expedited review and potential market exclusivity, reinforcing the company’s strategic positioning.
Management emphasized the urgent unmet need for effective therapies in metastatic osteosarcoma and highlighted the strategic advantage of comparative oncology, noting that canine trial data can accelerate human development. Historical market reactions to similar positive news have been muted, suggesting investors remain cautious about the company’s financial runway and commercialization prospects.
The BLA filing marks a significant regulatory milestone that could accelerate OST‑HER2’s path to market, but the company will need to navigate the remaining clinical data requirements and maintain investor confidence amid a competitive landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.